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Introduction: Cetuximab and bevacizumab have each been demon-
strated to prolong survival when added to chemotherapy in patients 
with advanced non–small-cell lung cancer (NSCLC). However, the 
potential benefit of combining cetuximab and bevacizumab together 
with a platinum-based doublet had not been explored. We designed 
this phase II trial to evaluate the safety, tolerability, and efficacy of 
the combination of carboplatin, paclitaxel, cetuximab, and bevaci-
zumab in chemotherapy-naive patients with advanced, nonsquamous 
NSCLC.
Methods: Patients received with up to six cycles of carboplatin (area 
under curve 6), paclitaxel (200 mg/m2), cetuximab (400 mg/m2 day 1 
then 250 mg/m2 weekly), and bevacizumab (15 mg/kg) every 21 days. 
Patients with an objective response or stable disease received main-
tenance cetuximab (250 mg/m2 weekly) and bevacizumab (15 mg/kg 
every 21 days) until disease progression. The primary endpoint was 
safety as defined by the frequency and severity of hemorrhagic tox-
icities. Secondary endpoints included response rate, progression-free 
survival, overall survival, and toxicity. Molecular biomarkers were 
assessed in an exploratory manner.
Results: The primary endpoint of grade 4 or higher hemorrhage of 
2% (95% confidence interval: 0%–7%) met prespecified criteria for 
safety. One hundred ten patients were enrolled. There were four treat-
ment-related deaths including lung hemorrhage (2), infection (1), 
and unknown (1). Median progression-free survival was 7 months 
and median overall survival was 15 months. The response rate was 
56% with an overall disease control rate of 77%.
Conclusion: This regimen was safe, feasible, and effective as a front-
line treatment of advanced NSCLC, providing the basis for the ongo-
ing phase III trial S0819.
Key Words: Non–small-cell lung cancer, Paclitaxel, Carboplatin, 
Cetuximab, Bevacizumab, Frontline.
(J Thorac Oncol. 2013;8: 1519–1528)
Progress in chemotherapy-based treatment of non–small-cell lung cancer (NSCLC) has been slow. Frontline treat-
ment has consisted of platinum-based doublets; typically 
producing median survivals of 8 to 10 months.1 Efforts to 
combine novel targeted agents with chemotherapy have been 
largely unsuccessful in the majority of trials, partly because 
of failure to account for the complex biology intrinsic to 
human lung cancers.2,3 An individual patient’s cancer, for 
example, may be dependent on multiple growth pathways, 
including vascular endothelial growth factor (VEGF) and 
epidermal growth factor receptor (EGFR). Thus, investigat-
ing combinations of targeted agents against these pathways 
is warranted.
Bevacizumab, a monoclonal, recombinant, humanized, 
murine antibody that targets VEGF, has been demonstrated 
to prolong overall survival (OS) when added to carboplatin 
and paclitaxel for chemotherapy-naive patients with nonsqua-
mous NSCLC4 in the E4599 study. In this randomized phase 
III trial, of carboplatin and paclitaxel with or without beva-
cizumab in patients with chemotherapy-naive, recurrent or 
metastatic, nonsquamous NSCLC, median progression-free 
survival (PFS) and OS increased from 4.5 and 10.3 months 
in the chemotherapy alone arm, respectively, to 6.2 and 12.3 
months in the chemotherapy plus bevacizumab arm (p < 0.05 
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for both). The Food and Drug Administration approved the 
bevacizumab NSCLC combination in October 2006.
Cetuximab, a chimerized immunoglobulin G1 antibody, 
blocks ligand-induced EGFR activation and has shown activ-
ity in multiple cancers including NSCLC. The phase III First-
Line Erbitux (FLEX) study of cisplatin and vinorelbine with 
or without cetuximab demonstrated increased OS in the cetux-
imab arm in patients with advanced EGFR-positive NSCLC.5 
In contrast, BMS 099, a phase III trial of chemotherapy with 
or without cetuximab in patients not preselected for EGFR 
status, failed to meet the primary endpoint of improved PFS, 
despite a numerically higher response rate (RR) and longer 
survival.6 Our predecessor trial SWOG 0342, a phase II trial of 
cetuximab with carboplatin and paclitaxel in advanced NSCLC 
patients, demonstrated tolerability and identified EGFR gene 
copy number as a potential predictive biomarker of efficacy.7 
Combination regimens targeting EGFR and VEGF pathways 
have been investigated in other tumor types with mixed suc-
cess.8–10 In NSCLC, trials using EGFR tyrosine kinase inhibi-
tors plus bevacizumab have shown improvements in PFS, but 
have failed to demonstrate statistically improved OS.11,12
Our study, SWOG 0536, (ClinicalTrials.gov Identifier: 
NCT00368992 http://clinicaltrials.gov/) sought to assess the 
safety, feasibility, and efficacy of a novel four-drug regimen, 
combining a chemotherapy doublet with a biologic doublet, 
in advanced NSCLC patients. We also explored the relation-
ship between potential predictive biomarkers for the EGFR 
and VEGF pathways and clinical outcomes.
PATIENT AND METHODS
Patient Eligibility
Patients had histologically confirmed, advanced-stage 
IIIB or IV nonsquamous NSCLC appropriate for frontline 
cytotoxic treatment and bevacizumab. Patients with squa-
mous cell carcinoma or brain metastases were ineligible. 
Patients must not have received any prior systemic NSCLC 
therapy (biologic, adjuvant). Patients must not have received 
prior EGFR or VEGF pathway agents, chimerized or murine 
monoclonal antibody therapy, or have documented presence 
of human antimouse antibodies. Prior radiation therapy and 
surgery were allowed. Patients must have normal organ func-
tion, a Zubrod performance status of 0 to 1, and age of 18 
years or more. Patients with any condition that carried a high 
risk of bleeding or with any nonhealing wound, ulcer, or bone 
fracture were ineligible.
The protocol was approved by the institutional review 
boards at participating institutions. Patients were informed of 
the investigational nature of the study and provided written 
informed consent in accordance with institutional and federal 
FIGURE 1.  CONSORT diagram.
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guidelines, including the banking of tumor, whole blood and 
serum specimens to explore relevant molecular parameters.
Treatment Plan
Patients received a loading dose of cetuximab 400 mg/m2 
IV on day 1. One week later, patients received cetuximab 
250 mg/m2 IV, paclitaxel 200 mg/m2 IV, carboplatin (area under 
the curve of 6) IV, and bevacizumab 15 mg/kg IV. Carboplatin, 
paclitaxel, and bevacizumab were administered every 3 weeks 
with cetuximab weekly. Cycles were repeated every 21 days for 
a maximum of six cycles. Patients with an objective response 
or stable disease received maintenance cetuximab (250 mg/m2 
weekly) and bevacizumab (15 mg/kg every 21 days) until dis-
ease progression, death, or intolerable toxicity.
Dose Modifications
Chemotherapy (i.e., carboplatin and paclitaxel) delays, 
dose reductions, and discontinuation were implemented accord-
ing to standard criteria prespecified in the protocol according 
to the National Cancer Institute Common Terminology Criteria 
of Adverse Events (version 3.0). For bevacizumab: dose reduc-
tions were not allowed; administration was delayed for grade 
3 toxicities (nonpulmonary hemorrhage, congestive heart 
failure, proteinuria) and grade 2 or higher bowel obstruction; 
permanent discontinuation for grade 3–4 hypertension. Patients 
who required a treatment delay of 4 weeks or more were not 
permitted to restart bevacizumab. Cetuximab dose reductions 
were infusion reactions, hypomagnesemia, and dermatologic or 
pulmonary toxicities. Grade 3 and 4 infusion reactions required 
discontinuation of cetuximab or bevacizumab.
Evaluations
All patients had baseline evaluation with history and 
physical examination, serum chemistry and hematologic tests, 
and imaging studies for assessment of disease status. Blood 
count, electrolytes, magnesium and liver function tests were 
obtained before each cycle. Proteinuria (urine protein cre-
atinine ratio or dipstick urinalysis) was monitored every two 
cycles. Imaging studies for assessment of treatment response 
were also obtained every two cycles. Tumor response by 
Response Evaluation Criteria in Solid Tumors criteria was 
assessed every two cycles.13
Study Endpoints and Statistical Analysis
The primary endpoint of the study was to evaluate the 
frequency and severity of hemorrhage-related toxicities, as 
defined by Common Terminology Criteria of Adverse Events. 
It was assumed if the true rate of grade 4–5 hemorrhage-
related toxicities was 10% or higher then this regimen would 
present an unacceptably high risk for further study. However, 
if the true rate were 3% or less then the risk of hemorrhage 
would be acceptable and the regimen would warrant further 
investigation, provided PFS, OS, and nonhemorrhage-related 
toxicities also seemed favorable.
The planned sample size was 90 evaluable patients to be 
enrolled over 5 months. If five or more patients experienced 
grade 4–5 hemorrhage at any point, the trial would be closed 
with the conclusion that the frequency of grade 4–5 hemor-
rhage toxicities was too high to warrant further study of the 
regimen. This design had 87% power using a one-sided exact 
test based on the binomial distribution with a significance level 
of 5%. In addition, assuming 12 months of follow-up, this 
design would also have 82% power, (using a test of medians 
with a one-sided α of 0.05) to rule out the null hypothesis of an 
8-month median survival versus an alternative of a 12-month 
median survival. An observed median survival of 10 months 
or longer would be considered evidence that this regimen war-
rants further testing provided this regimen is considered safe 
based on the outcome of the primary study objective.
Other secondary endpoints included PFS, RR (con-
firmed plus unconfirmed, complete plus partial) in the sub-
set of patients with measurable disease at baseline (Response 
Evaluation Criteria in Solid Tumors), and the overall toxicity 
profile. Ninety patients would allow for the estimation of RR 
and toxicity rates to within ± 11% (95% confidence interval 
[CI]). Any toxicity occurring with at least 5% probability was 
highly likely to be seen at least once (99%).
All eligible patients who received at least one dose of 
the study drug were analyzed for efficacy and toxicity end-
points. Continuous variables are presented using median 
(range), with any comparisons made using either the t test 
or Wilcoxon rank sum test, depending on the observed 
TABLE 1.  Baseline Patient Characteristics
Characteristic Number of Patients (%) N = 102
Median age, yrs (range) 64 (42–78)
Performance status
  0 42 (41%)
  1 60 (59%)
Sex
  Female 50 (49%)
  Male 52 (51%)
Ethnicity
  White 89 (87%)
  African American 6 (6%)
  Asian/Pacific Islander 3 (3%)
Other 4 (4%)
  Smoking status
  Never smoker 22 (22%)
  Former/current smoker 80 (78%)
Histology
  Adenocarcinoma 81 (79%)
  Other 21 (21%)
Stage
  IIIB 7 (7%)
  IV 95 (93%)
Weight loss (last 6 months)
  <5% 69 (68%)
  5 to <10% 18 (18%)
  10–20% 13 (13%)
  >20% 1 (1%)
  Not reported 1 (1%)
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distribution. Categorical variables are summarized in fre-
quency tables, with any comparisons made using Fisher’s 
exact test. OS and PFS estimates were computed using the 
method of Kaplan and Meier14 and confidence intervals for the 
medians were constructed using the method of Brookmeyer 
and Crowley.15
Biomarker Studies
Correlative analyses were performed to explore associa-
tions between clinical outcomes and tumor-associated EGFR 
pathways biomarkers (mutational status, gene copy number, 
protein expression) and KRAS mutation status, including iden-
tification of potential cut points in marker levels to guide cor-
relative studies in future trials. Cox regression techniques16 
were used to assess the associations between markers and OS 
and PFS. Fisher’s exact test was used to assess the associa-
tion with RR and disease control rate (DCR). In addition, the 
association between clinical outcomes and a selected subset 
of 35 plasma circulating cytokine-angiogenesis factors (CAF) 
were explored. We investigated baseline levels of these mark-
ers and the percent change between baseline and levels at 
week 5 of treatment. Raw data were converted to ranks and 
the ranks were transformed into a percentile between 0 and 1. 
Cox regression was used to investigate PFS and OS, and logis-
tic regression was used to evaluate RR and DCR. As these 
analyses were for exploratory purposes, unadjusted p values 
are provided.
RESULTS
Between August 2006 and September 2007, 110 patients 
were enrolled in the study (Fig. 1). Five patients were ineligi-
ble: three who had squamous cell histology, and two who did 
not have the correct stage. Three eligible patients refused pro-
tocol treatment and were not analyzable for any of the study 
endpoints, leaving 102 evaluable patients. Table 1 shows base-
line patient characteristics.
Toxicity Results
The primary endpoint of grade 4 or higher hemorrhage 
was 2% (95% CI: 0%–7%). Both patients had grade 5 pul-
monary hemorrhage. There were two additional treatment-
related deaths: one from infection and one with cause of death 
unknown. Overall toxicities were acceptable and comparable 
to reference trials S0342 and E4599.7,4 A summary of selected 
grade 3–5 toxicities is presented in Table 2. The most common 
adverse events (grade ≥3) were acneiform rash, neutropenia, 
infection, neuropathy, and fatigue.
Efficacy Results
In ninety-five patients with measurable disease the 
overall RR was 56% (52 of 95; 44%–65%). Overall DCR was 
77% (stable disease 21 of 95; 22%). The estimated median 
PFS was 7 months (95% CI: 6–8 months) and median OS 
was 15 months (95% CI: 11–21 months). One-year survival 
is 57% (95% CI: 47%–66%; Fig. 2). The median follow-up 
TABLE 2.  Selected Grade 3–5 Adverse Events
Grade 3 Grade 4 Grade 5 Total
Hematologic
  Febrile neutropenia 5 5% 1 1% 0 0% 6 6%
  Hemoglobin 3 3% 0 0% 0 0% 3 3%
  Neutrophils 23 23% 27 26% 0 0% 50 49%
  Platelets 3 3% 1 1% 0 0% 4 4%
Nonhematologic
  Allergic reaction 7 7% 0 0% 0 0% 7 7%
  Death, NOS 0 0% 0 0% 1 1% 1 1%
  Dehydration 5 5% 1 1% 0 0% 6 6%
  Dermatologic/skin 27 26% 0 0% 0 0% 27 26%
  Diarrhea 5 5% 0 0% 0 0% 5 5%
  Dyspnea 7 7% 2 2% 0 0% 9 9%
  Fatigue 17 17% 2 2% 0 0% 19 19%
  GI perforation: colon 1 1% 0 0% 0 0% 1 1%
  Hypertension 2 2% 0 0% 0 0% 2 2%
  Hypokalemia 6 6% 1 1% 0 0% 7 7%
  Hypomagnesemia 3 3% 2 2% 0 0% 5 5%
  Infection 12 12% 1 1% 1 1% 14 14%
  Lung hemorrhage 1 1% 0 0% 2 2% 3 3%
  Nausea/vomiting 8 8% 0 0% 0 0% 8 8%
  Neuropathy—motor/sensory 15 15% 2 2% 0 0% 17 17%
  Proteinuria 1 1% 0 0% 0 0% 1 1%
  Thrombosis/embolism 2 2% 7 7% 0 0% 9 9%
NOS, not otherwise specified; GI, gastrointestinal.
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time among the 17 patients still alive is 42 months (range, 
32–51 months).
Treatment Delivery
The median number of cycles received during cycles 1 
to 6 was 4 (range, 1–6). Forty-seven patients (46%) went on to 
receive maintenance treatment. The median number of main-
tenance cycles received was 12 (range, 7–47).
Biomarker Results
Analyzable tumor specimens were available from 66 
patients for one or more correlative science studies, prioritized 
in the following order: EGFR gene copy number, by fluo-
rescent in situ hybridization (FISH), KRAS mutation, EGFR 
mutation, and EGFR protein by expression by immunohisto-
chemistry. Tumor specimens were classified as EGFR FISH 
positive if there were four or more gene copies per cell in at 
least 40% of the cells (high polysomy) or gene amplification. 
Results from the correlative analysis of biomarkers and clinical 
outcomes are presented in Table 3. EGFR FISH was assessable 
in 50 patients, and 26 (52%) were EGFR FISH positive (20 
high polysomy, 6 gene amplification). Although the RR and 
DCR were numerically higher in EGFR FISH-positive can-
cers (64% versus 45% and 88% versus 73%), these differences 
were not statistically significant (RR: p = 0.25; DCR: p = 0.27). 
EGFR FISH-positivity was not significantly associated with 
other clinical outcomes [PFS: p = 0.91; OS: p = 0.13] (Fig. 3A).
KRAS mutation status was assessable in 32 patients and 
28% harbored KRAS mutations. No statistically significant 
associations were observed between KRAS mutation status 
and clinical outcomes (RR: p = 1.00; DCR: p = 1.00; PFS: 
p = 0.27; OS p = 0.49; Fig. 4), although similar to our prior 
observation in S0342, patients with KRAS mutation had 
numerically longer PFS and OS.
EGFR mutation status was assessable in 31 patients and 
16% harbored EGFR mutations. No statistically significant 
associations were observed between EGFR mutation status and 
clinical outcomes (RR: p = 1.00; DCR: p = 0.27; PFS: p = 0.11; 
OS: p = 0.41).
EGFR protein expression by immunohistochemistry 
was assessable in 64 patients. The median H Score was 150 
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FIGURE 2.  Kaplan–Meier curves 
for progression-free survival (A) and 
overall survival (B).
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(range, 0–300). Four different dichotomous cut points were 
analyzed: H score 0 (47 patients) versus 0 or higher (17 
patients), 100 or more (35 patients) versus less than 100 
(29 patients), 200 or more (23 patients) versus less than 
200 (41 patients), and H score = 300 (10) versus less than 
300 (54 patients). Although high H scores trended toward 
better RR, PFS, and OS, there were no statistically signifi-
cant associations between clinical outcomes for any of the 
four cut points.
The association between plasma levels of circulating 
CAF and clinical outcomes was investigated. Plasma samples 
were available from 74 patients. In this exploratory analysis, 
higher baseline levels of Hu platelet-derived growth factor-bb 
(47) were associated with better PFS (p = 0.03). Higher baseline 
levels of Hu hepatocyte growth factor (HGF) (62) (p < 0.01), 
matrix metalloproteinase-9 (27) (p = 0.04), and osteopontin 
(p = 0.02) were associated with worse OS. Higher baseline 
levels of human (HU) HGF (62) (p < 0.03), matrix metal-
loproteinase-9 (27) (p = 0.049), HU interleukin (IL)-18 (42) 
(p = 0.01), HU stem cell growth factor (SCGF)-b (78), and HU 
VEGF (45) were associated with a worse DCR, whereas a high 
baseline level of sVEGFR2 was associated with a better DCR. 
Increased levels over baseline at week 5 of HU monocyte che-
motactic protein (MCP)-3 (26) (p = 0.04) and HU TNF-related 
apoptosis-inducing ligand (TRAIL) (66) (p = 0.04) were asso-
ciated with worse PFS. Increases in HU granulocyte-macro-
phage colony-stimulating factor (GM-CSF) (34) (p = 0.03), HU 
interferon (IFN)-g (21) (p = 0.02), HU macrophage inflamma-
tory protein (MIP)-1a (55) (p = 0.01), and HU platelet-derived 
growth factor (PDGF)-bb (47) (p = 0.01) were associated with 
worse OS, whereas increases in osteopontin (p = 0.01) and 
CA-9 (p = 0.04) were associated with better OS. An increase 
over baseline in the level of HU G-CSF (57) was associated 
with a higher RR. Increases in HU IL-16 (27), HU IL-18 (42), 
HU IL-9 (77), and HU MCP-1(MCAF) were associated with 
a higher DCR.
Finally, clinical outcomes and selected baseline char-
acteristics were compared between patients with assessable 
specimens (tissue or blood, n = 84) versus those in which spec-
imens were not assessable (n = 18; Table 4; Supplementary 
Table, Supplemental Digital Content 1, http://links.lww.
com/JTO/A484). There was no significant difference in 
TABLE 3.  Results of Biomarker Analysis
Biomarker PFS Hazard Ratio 95% CI p OS Hazard Ratio 95% CI p
KRAS mutation 0.64 0.29–1.42 0.27 0.74 0.30–1.78 0.49
EGFR mutation 2.35 0.83–6.65 0.11 0.60 0.18–2.03 0.41
EGFR FISH positive 1.03 0.59–1.82 0.91 0.61 0.33–1.15 0.13
  High polysomy 0.94 0.52–1.68 0.83 0.69 0.36–1.33 0.27
  Gene amplification 1.26 0.53–3.02 0.60 0.76 0.29–1.99 0.58
EGFR IHC >0 0.90 0.51–1.57 0.70 0.63 0.34–1.15 0.13
EGFR IHC ≥100 0.71 0.43–1.19 0.19 0.62 0.36–1.08 0.09
EGFR IHC ≥200 0.70 0.42–1.19 0.19 0.88 0.50–1.55 0.65
EGFR IHC = 300 0.53 0.26–1.08 0.08 0.54 0.24–1.21 0.14
Biomarker RR p DCR p
KRAS mutation 57% 1.00 86% 1.00
KRAS wild type 52% 78%
EGFR mutation 60% 1.00 60% 0.27
EGFR wild type 54% 83%
EGFR FISH-positive 64% 0.25 88% 0.27
EGFR FISH-negative 45% 73%
EGFR FISH high polysomy 58% 1.00 89% 0.28
None 54% 75%
EGFR FISH gene amplification 83% 0.20 83% 1.00
None 51% 80%
EGFR IHC >0 56% 1.00 82% 0.72
EGFR IHC = 0 56% 75%
EGFR IHC ≥100 62% 0.31 79% 1.00
EGFR IHC <100 48% 81%
EGFR IHC ≥200 55% 1.00 77% 0.74
EGFR IHC <200 56% 82%
EGFR IHC = 300 56% 1.00 78% 1.00
EGFR IHC <300 56% 81%
PFS, progression-free survival; CI, confidence interval; OS, overall survival; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; RR, response rate; DCR, disease 
control rate; EGFR, epidermal growth factor receptor; KRAS, kirsten rat sarcoma.
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performance status (p = 1.00), sex (0.44), race (white versus 
all others; p = 0.69), histology (adenocarcinoma versus all oth-
ers; p = 0.52), smoking status (never versus current/former; 
p = 0.35), tumor, node, metastasis stage (p = 0.35), OS (HR: 
submitted specimen versus none: = 0.66; 95% CI: 0.38–1.13; 
p = 0.13), RR (p = 0.78), or DCR (p = 0.18). However, patients 
who submitted specimens had a significantly better PFS (HR 
= 0.59; 95% CI: 0.35–1.00; p = 0.047).
DISCUSSION
SWOG S0536 is the first study to evaluate the com-
bination of platinum-based chemotherapy plus cetuximab 
and bevacizumab in patients with advanced-stage NSCLC. 
Using the E4599 and S0342 trials4,7 as reference regimens, 
the four-drug S0536 regimen was not associated with excess 
toxicity, notably pulmonary hemorrhage. Bleeding (including 
hemoptysis) has been associated with bevacizumab treatment 
for NSCLC, even in patients with nonsquamous histology. 
In E4599, bleeding of grade 3 or more occurred in 22 of 
427 bevacizumab-treated patients (5.2%), with hemoptysis 
occurring in eight patients (1.9%).4 In Avastin in Lung can-
cer (AVAiL), bleeding of grade 3 or more occurred in 28 of 
659 bevacizumab-treated patients (4.2%), with hemoptysis in 
eight patients (1.2%).17
Further, we observed efficacy outcomes warranting 
further study, with a response rate of 54%, PFS of 7 months 
and OS of 15 months. These phase II efficacy results com-
pare favorably with other experiences with triplet regimens 
based on cetuximab or bevacizumab, including E4599, 
AVAiL, FLEX, BMS 099, and S0342.4–7,17 The percentage of 
patients who completed induction chemotherapy and went on 
to maintenance treatment was 46%. This compares with 60% 
in the E4599 and 42% in AVAiL. The OS and PFS observed in 
E4599 for the bevacizumab-containing arm were 12.3 months 
and 6.2 months, and in AVAIL were 13.4 months (bevaci-
zumab 7.5 mg/kg) and 13.6 months (bevacizumab 15 mg/
kg), and 6.5 months (bevacizumab 7.5 mg/kg) and 6.7 months 
(bevacizumab 15 mg/kg), respectively.
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FIGURE 3.  Progression-free survival 
(A) and overall survival (B) by EGFR 
FISH status. EGFR, epidermal growth 
factor receptor; FISH, fluorescent in 
situ hybridization.
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The FLEX study, a large trial of more than 1000 patients, 
demonstrated an OS (primary endpoint) improvement of 11.3 
versus 10.1 months.5 In comparison, the smaller BMS 099 
study6 showed no benefit in PFS (primary endpoint) despite 
improved RR and OS (9.7 versus 8.4 months).
Our predecessor phase II SWOG study S0342, which 
tested a combination of carboplatin, paclitaxel, and cetuximab 
in two different schedules (concurrent or sequential) reported 
OS (10.7 and 10.9 months) and PFS (4.3 and 4.4), respec-
tively.6 S0536 built upon this S0342 platform by adding beva-
cizumab, based on benefits seen for bevacizumab in E4599 
and AVAiL, plus data supporting combined VEGF-EGFR–
directed therapy.
Results of clinical trials combining EGFR and VEGF 
blockade have shown mixed results and may be tumor type 
specific. In two recently reported colorectal cancer stud-
ies, the addition of cetuximab and bevacizumab to existing 
chemotherapy regimens failed to demonstrate benefit. One 
study randomized 755 patients with previously untreated 
metastatic colorectal cancer to capecitabine, oxaliplatin, 
and bevacizumab with or without cetuximab for metastatic 
colorectal cancer.8 Another study randomized more than 
1000 patients to receive chemotherapy (oxalipatin or irinote-
can-based) with bevacizumab with or without panitumumab, 
a fully human antibody targeting the EGFR.9 In both studies, 
PFS was lower and toxicity increased in the EGFR antibody-
containing arm. Combinations of erlotinib with bevacizumab 
in phase III trials have been more promising (Bevacizumab 
and Tarceva [BeTa], Avastin and Tarceva in Lung with Lung 
Cancer [ATLAS]).11,12
The currently ongoing S0819 is designed to directly test 
the hypothesis of combined EGFR-VEGF blockade together 
with chemotherapy. This phase III biomarker validation study 
compares carboplatin–paclitaxel with or without cetuximab, 
and allows inclusion of bevacizumab in both arms, based on 
previously reported bevacizumab eligibility criteria (E4599). 
S0819 incorporates EGFR FISH as a coprimary endpoint, 
based on our previous observations from S0342 that EGFR 
FISH-positive patients demonstrated improved response, 
PFS, and OS with paclitaxel–carboplatin–cetuximab. S0536 
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also explored a variety of potential prognostic and/or pre-
dictive biomarkers, with particular attention to whether the 
addition of bevacizumab would alter previously described 
associations from other cetuximab-based studies such as 
S0342 or FLEX. In S0536, although FISH-positive patients 
had a trend for higher RR and DCR, outcome differences 
were not statistically significant. This difference may merely 
reflect the exploratory nature of these observations in serial 
phase II studies and the retrospective nature of the H score 
observation from FLEX. Regardless, the S0819 phase III 
trial is designed to account for a bevacizumab effect within 
the statistical design. On the basis of the S0536 observations 
described here, additional biomarkers such as EGFR protein 
H score and CAF profiling, which we present as preliminary 
results here, are being evaluated in the phase III S0819 study 
as well. Finally, KRAS mutation status was not associated 
with a detrimental effect on efficacy parameters in S0536, 
mimicking our S0342 results as well as those from retro-
spective analyses of FLEX and BMS099, and in contrast to 
reports from multiple trials of cetuximab-based therapy in 
colorectal cancer.18,19
In conclusion, S0536, the first reported study to com-
bine carboplatin, paclitaxel, cetuximab, and bevacizumab, 
demonstrates that the regimen is safe, feasible, and efficacious 
as first-line treatment for advanced nonsquamous, non–small-
cell lung cancer. Further evaluation of this regimen is ongoing 
in the phase III trial S0819.
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